These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 21365598

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE.
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [Abstract] [Full Text] [Related]

  • 3. Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.
    Ruocco LA, Carnevale UA, Treno C, Sadile AG, Melisi D, Arra C, Ibba M, Schirru C, Carboni E.
    Behav Brain Res; 2010 Jun 26; 210(1):99-106. PubMed ID: 20156489
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [New therapeutic options in the treatment of attention deficit/hyperactivity disorder].
    Artigas Pallares J.
    Rev Neurol; 2004 Feb 26; 38 Suppl 1():S117-23. PubMed ID: 15011165
    [Abstract] [Full Text] [Related]

  • 9. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
    Prince JB.
    Child Adolesc Psychiatr Clin N Am; 2006 Jan 26; 15(1):13-50. PubMed ID: 16321724
    [Abstract] [Full Text] [Related]

  • 10. [Current evidence about atomoxetine. A therapeutic alternative for the treatment of attention deficit hyperactivity disorder].
    Velásquez-Tirado JD, Peña JA.
    Rev Neurol; 2006 Jan 26; 41(8):493-500. PubMed ID: 16224736
    [Abstract] [Full Text] [Related]

  • 11. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.
    Arnsten AF.
    J Clin Psychiatry; 2006 Jan 26; 67 Suppl 8():7-12. PubMed ID: 16961424
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS.
    Drugs Today (Barc); 2013 Oct 26; 49(10):647-65. PubMed ID: 24191257
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain.
    Easton N, Steward C, Marshall F, Fone K, Marsden C.
    Neuropharmacology; 2007 Feb 26; 52(2):405-14. PubMed ID: 17020775
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
    Husarova V, Bittsansky M, Ondrejka I, Dobrota D.
    Psychiatry Res; 2014 Apr 30; 222(1-2):75-83. PubMed ID: 24679996
    [Abstract] [Full Text] [Related]

  • 20. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 30; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.